- Poster presentation
- Published:
Serum tobramycin levels during selective decontamination of the digestive tract in ICU patients on renal replacement therapy
Critical Care volume 12, Article number: P24 (2008)
Introduction
Selective decontamination of the digestive tract (SDD) is an infection prophylaxis regimen that may improve survival in ICU patients [1]. Antibiotics for SDD are nonabsorbable, are given enterally and are therefore considered safe to use. The aim of our study was to determine whether enteral administration of tobramycin as part of a SDD regimen may lead to detectable and potentially toxic serum tobramycin concentrations in patients with renal failure.
Methods
A prospective, observational study in ICU patients given SDD treatment for at least 3 days. All patients were on continuous venovenous hemofiltration with a filtration rate of 35 ml/kg/hour. Tobramycin serum concentrations were measured every 3 days.
Results
Serum samples were taken a median 6 days after the start of SDD (IQR 3–9 days). Detectable tobramycin levels were found in 12 of 19 patients (63%) and in 15 of 26 serum samples (58%). In four patients tobramycin concentrations were ≥ 1 mg/l, and in one of these patients a toxic concentration of 3 mg/l was found. All patients with tobramycin levels >1 mg/l had ischemic bowel disease. In contrast, no patients with lower concentrations had intestinal ischemia.
Conclusion
In patients with renal failure treated with continuous venovenous hemofiltration, administration of SDD can lead to detectable and potentially toxic tobramycin serum concentrations. The risk of increased enteral absorption of tobramycin may be particularly high in patients with intestinal ischemia. We advise monitoring plasma tobramycin concentrations in patients with renal failure on prolonged treatment with SDD.
References
de Jonge E, et al: Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet. 2003, 362: 1011-1016. 10.1016/S0140-6736(03)14409-1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mol, M., Van Kan, H., Spanjaard, L. et al. Serum tobramycin levels during selective decontamination of the digestive tract in ICU patients on renal replacement therapy. Crit Care 12 (Suppl 2), P24 (2008). https://doi.org/10.1186/cc6245
Published:
DOI: https://doi.org/10.1186/cc6245
Keywords
- Digestive Tract
- Renal Replacement Therapy
- Tobramycin
- Intestinal Ischemia
- Ischemic Bowel